AREN1721, a randomized phase 2 trial of axitinib+nivolumab combination therapy vs. single agent nivolumab for the treatment of TFE/translocation renal cell carcinoma (tRCC) across all age groups, an NCI National Clinical Trials Network (NCTN) phase 2 study.

Nicholas G. Cost, James I. Geller, Matthew R. Zibelman et al.|Journal of Clinical Oncology|2025

Cited by 7